Clinical trials are currently conducted combining ATR and Chk1 inhibitors with anti-PD-(L)1 antibodies in solid tumors including HNSCC (NCT04266912, NCT02264678, NCT04095273, NCT03495323) [246]. The gene discussed is CHEK1; the disease is head and neck squamous cell carcinoma.